FyMed, Inc.

Press Releases

FyMed Demonstrates Superiority of FY101C over Ibuprofen and Naproxen In the Treatment of Pain and Inflammation

FyMed, Inc. today announced results from comparative in-vivo studies of FY101C, its lead NSAID candidate, which demonstrated significant superiority to conventional NSAIDs in terms of efficacy and safety in the management of acute and chronic pain and inflammation. Read More...